U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

		-				Compl	lete if Kı	nown		
Substitute t	for Form	1449/A/PTO			Filing Date 03/8		799,163			
_	_						03/1	03/12/2004		
		EMATION DIS					Johr	W. Holaday		
	•	MENT BY A		NT	Group Art Un	it	165	3		
AUS 1 6	2004	use as many sheets as ne	cessary)		Examiner Nan	ne	Una	ssigned		
Sheet	, é	of 4			Attorney Dock	et Number	052	13-0077 (43170-296614)		
Sheet	E PARTY				<u> </u>					
	-		U.S	. PATENT	DOCUMENTS					
Examiner	Cite	U.S. Patent Docur				Date of Publ		Pages, Columns, Lines, Where Relevant Passages or		
Initials	No.'	Number*	Kind Code (if known)		of Patentee or f Cited Document	of Cited Docume MM-DD-YYYY		Relevant Figures Appear		
CY	1	5,252,718	Α	Baird et al.		10/12/19	993			
	2	5,288,704	A	Ungheri et al		02/22/19	994			
	3	5,629,327		D'Amato		05/13/19	97			
	4	5,639,725		O'Reilly et a	l,	06/17/19	997			
	5	5,733,876		O'Reilly et a	1.	03/31/19	998			
	6	5,792,845		O'Reilly et a	1.	08/11/1998				
	7	5,854,205		O'Reilly et a	1.	12/29/19	98			
	8	5,919,459	A	Nacy et al.		07/06/19	999			
$\overline{\Psi}$	9	6,346,510	BI	O'Reilly et a	l.	02/12/20	002			
CY	10	6,413,513	B1	Holaday, Joh	un .	07/02/20	002			

Examiner	•	Date	06/06/0006
Signature	/Christopher Yaen/ (06/26/2006)	Considered	06/26/2006
	<u> </u>	l	

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

-						Ele tedament in its	<u> </u>	Compl	ete if Kr	nown		
Substitute f	or Form	1449/A/	рто				Application No.		10/79	0/799,163		
									03/12/2004			
INFORMATION DISCLOSURE						URE	First Named In	ventor	John	W. Holaday		
S	ΓΑΤ	EME	ENT BY	AP	PLIC.	ANT	Group Art Uni	t	1653			
		(use as	many sheet	s as nece	ssary)		Examiner Nam	ne	Unas	signed		
Sheet		2	of 4				Attorney Dock	et Number	0521	3-0077 (43170-296614)		
			<u> </u>									
					FO	REIGN PATI	ENT DOCUME	NTS				
Examiner	Cite	F	oreign Paten		nt			Date of Publ		Pages, Cotumns, Lines, Where Relevant Passages or	r	
Initials	No.'	Office	Number*		nd Code inown)		f Patentee or Cited Document	of Cited Document MM-DD-YYYY		Relevant Figures Appear	Ш	
СУ	11	ЕР	028182	22	A2	Takeda Chemica	cal Industries, Ltd. 09/14/19		988			
		·									1	
CY	12	EP	06571	75	A2	Centro de Immu	nologia Molecular	06/14/19	995			
								09/12/19	007	<u></u>	Т	
CY	13	Japa	093160	900	A	Toagosei Co. Li	d.	09/12/19				
	14	- I wo I	94/212	99	Al	Assay Research	Inc.	09/29/1	994	T	Ι	
CY			<del></del>									
CY	15	wo	94/276	35	A	EntreMed, Inc.		12/08/1	994		T	
	<u> </u>				<u> </u>			L			<u> </u>	
CY	16	wo	99/450	18	Al	Imclone System	s Incorporated	09/10/1	999			

Examiner Signature	/Christopher Yaen/ (06/26/2006)	Date Considered	06/26/2006

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

r	Olidei di	t raper.				Complete if Known					
		C	1449/A/PTO			Application No.		10/799,1	163		
OIP	E\					Filing Date		03/12/20	004		
,	S.AL	(FO	RMATIO	N DISCL	OSURE	First Named In	ventor	John W.	Holaday		$\Box$
AUS 1 B	20045	TAT	EMENT I	BY APPL	ICANT	Group Art Unit		1653			
	a)			heets as necessary		Examiner Nam	e	Unassig	ned		
(B)	- C/	Sheet 3 of 4					et Number	. 05213-0	077 (43170	)-296614)	
Pre MAD	Sheet		3 of			<u></u>					
					ART - NON PAT	ENT LITED AT	IDE DOCI	IMENTS			一
		—-т	1	luda nama aftha	outhor (in CAPITAL I	ETTERS), title of the	e article (wher	appropriate),	title of the		T
	Examiner Initials	Cite No.'	iten	n (book, magazin	e, journal, serial, symp publisher, city	osium, catalog, etc.), and/or country where	date, page(s), published	AOIMING-1220C	numoci(s),		
		17	Author: BAIRD	et al.	Title: Receptor-	and Heparin-Binding	Domains of B	asic Fibroblas	t Growth Fa	actor	
	av.		Publ:								
	CY		Proceedings of th	e National Acade	my of				D.4	044000	
			Sciences		Vol/lss:		Pages: 232		Date:	04/1988	ᆛ
		18	Author: BALIA	N et al.	Title: Structure	of Rat Skin Collage imine-Produced Fra	nα1-CB8. An ament HA2	nino Acid Se	quence of	the	
	CY		Publ:		riyuloxyic	111110-1 1000000 1 10	<b>3</b>				
			Biochemistry				Pages:		Date:		1
			L		Vol/lss:			/- b. Tiense I		yey Inhihitor	=
		19	Author: ENJYO	JI, K. et al.	Title: Effect of I Segment,	leparin on the Inhibit Gly <sup>112</sup> - Phe <sup>20</sup> , of the	third Kunitz C	omain is a He	eparin-Bind	ing Site	
	]		Publ:								
	CY	l	Biochemistry		Vol/lss:	34 (17)	Pages: 572	25-5735	Date:	1995	$\perp$
			L			giogenesis: Therapeu	tic Implication	15			T
	}	20	Author: FOLKN	AAN, J.	THE THIRT I	.0.0B*	•				
	CY		Publ: New England Jos	urnal of Medicine						•	
		1				285 (21)	Pages: 111	82-1186	Date:	11/18/71	
		21	Author: PLUM	et al.	Title: Vaccinati	ona with Peptide to th	e Heparin Bin	ding Domain	of bFGF C	onjugated to	T
		] -	Publ:	** *	Liposomo	s Inhibits bFGF Indu	ced Neovascul	arization (Ab	suaci onia)		
	CY		Proceedings of the	he American Asso	ociation for						
	Cancer Research Annual.				Vol/lss:		Pages: 8		Date:	03/1998	<del> </del>
	22 Author: PLUM et al. Title					ration of a Liposomal ediated Angiogenesis	FGF-2 Peptid	e Vaccine Les	ads to Abro	gation of	
	1		Publ:		FOF-2-W	chiaten Villiogenesis	. 200 , 2011.01 2	• • • • • • • • • • • • • • • • • • • •			
	CY	1	Vaccine				D 40	04 1003	D-4	0000	
		<u> </u>				: 19 (9-10)	Pages: 12		Date:	2000	<del>+-</del>
		23	Author: SEAV	ER, Sally	Title: Monoclo	nal Antibodies in Ind	ustry: More Di	fficult than O	riginally Ti	wugnt	
	CY		Publ:								1
			Genetic Enginee	ering News	17-10	.14	Pages: 10	and 21	Date:	08/1994	
	1	1			Vol/Iss	, 14					

Examiner Signature /Christopher Yaen/ (06/	Date Considered	06/26/2006

'Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	inder the Paperwork Reduction Act of 1993, no person 2014						Complete if Known					
Substitute	for For	n 1449/A/PT	0				Application N	0.	10/79	9,163		
							Filing Date		03/12/2004			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						SURE	First Named I	nventor	John W. Holaday 1653			
						CANT	Group Art Ur	nit				
	(use as many sheets as necessary)						Examiner Na	me	Unassigned			
Sheet	Т	4 of 4					Attorney Doc	ket Number	05213	3-0077 (431	70-296614)	
							<del></del>					
			ОТИ	FD DI	TOP AT	PT - NON PAT	TENT LITERAT	URE DOCU	MENTS	}	<del></del>	
		<u> </u>	UIA	CK FF	a of the or	ther (in CAPITAL	LETTERS), title of t	he article (when	appropriat	e), title of th	ne	
Examiner	Cite		item	ude nam (book,	nagazine,	iournal serial syn	mosium, catalog, etc.	), date, page(s), v	olume-issi	ue number(s	i),	T
Initials	No.			<u> </u>		publisher, city	y and/or country wher	e published				누
	24	Author: SC	KER (	Author: SOKER et al.  Title:Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor							1	
		•					C. Marandan Padasha					
		Publi				Receptor	for Vascular Endothe	elial Growth Fact	OT			ı
CY		Publ: <u>Cell</u>				Receptor	for Vascular Endothe	cial Growth Fact	or			
CY		r				Receptor Vol/lss	for Vascular Endothe	Pages: 735-		Date:	03/20/1998	
CY	25	r	LARI		<del></del> _	Vol/Iss	for Vascular Endothe	Pages: 735- mor Growth by I	745		03/20/1998	
CY	25	Cell Author: T/		CO et al		Vol/Iss Title: Protectio Oncogen	for Vascular Endothe	Pages: 735- mor Growth by I	745		03/20/1998	
СУ	25	Author: TA		CO et al		Vol/Iss Title: Protectio Oncogen	for Vascular Endother: 92 n of Mice Against Tue-Encoded Growth Fa	Pages: 735- mor Growth by I	745 mmunizati	on with an		
	25	Cell Author: T/		CO et al		Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss	for Vascular Endother: 92  n of Mice Against Tue-Encoded Growth Fig. 187	Pages: 735- mor Growth by I actor Pages: 4222	745 Immunizati 2-4225	on with an	06/1990	
	25	Author: TA	of the	CO et al	il Academ	Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss	for Vascular Endother: 92 n of Mice Against Tue-Encoded Growth Fa	Pages: 735- mor Growth by I actor Pages: 4222	745 mmunizati 2-4225 id A: Enha	Date:	06/1990 Liposomal	
		Author: TAPubl: Proceeding: USA  Author: Vi Publ:	s of the	CO et al	il Academ	Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss	for Vascular Endother: 92 n of Mice Against Tu e-Encoded Growth Fi	Pages: 735- mor Growth by I actor Pages: 4222	745 mmunizati 2-4225 id A: Enha	Date:	06/1990 Liposomal	
СУ		Author: TAPubl: Proceeding: USA Author: Vi	s of the	CO et al	il Academ	Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss Title: Adjuvant	for Vascular Endothers: 92  n of Mice Against Tu e-Encoded Growth Face: 87  t Effects of Liposome Presentation and Reco	Pages: 735- mor Growth by I actor Pages: 4222 s Containing Lip ruitment of Macro	745 mmunizati 2-4225 iid A: Enha ophages (A	Date:	06/1990 Liposomal y)	
СУ		Author: TAPubl: Proceeding: USA  Author: Vi Publ:	s of the	CO et al	il Academ	Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss Title: Adjuvant Antigen	for Vascular Endother ::92  n of Mice Against Tu e-Encoded Growth Fi s:87  t Effects of Liposome Presentation and Recu s:60 (6)	Pages: 735- mor Growth by I actor  Pages: 4222 s Containing Lip ruitment of Macr	745 mmunizati 2-4225 iid A: Enha ophages (A	Date: ancement of abstract only	06/1990 Liposomal y)	
СУ		Author: T/Publ: Proceeding: USA  Author: Vi Publ: Infect, Imm	erma	CO et al	il Academ	Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss Title: Adjuvant Antigen  Vol/Iss	for Vascular Endothers: 92  n of Mice Against Tu e-Encoded Growth Face: 87  t Effects of Liposome Presentation and Reco	Pages: 735- mor Growth by I actor  Pages: 4222 s Containing Lip ruitment of Macr	745 mmunizati 2-4225 iid A: Enha ophages (A 8-2444 uman CD-4	Date: ancement of abstract only	06/1990 Liposomal y)	
СУ	26	Author: TAPubl: Proceeding: USA  Author: VI Publ: Infect, Imm	ERMA	CO et al	IG et al.	Vol/Iss Title: Protectio Oncogen y of Science Vol/Iss Title: Adjuvant Antigen  Vol/Iss	for Vascular Endother ::92  n of Mice Against Tu e-Encoded Growth False:87  t Effects of Liposome Presentation and Recu s: 60 (6)	Pages: 735- mor Growth by I actor  Pages: 4222 s Containing Lip ruitment of Macr	745 mmunizati 2-4225 iid A: Enha ophages (A 8-2444 uman CD-4	Date: ancement of abstract only	06/1990 Liposomal y)	

Examiner	/Christopher Yaen/ (06/26/2006)	Date Considered	06/26/2006